Theratechnologies Inc. (THTX) presented encouraging results from PROMISE-US, a Phase 4 study of ibalizumab in heavily treatment-experienced people with HIV, the company said in a statement on Wednesday.
The study is designed to evaluate the long-term efficacy and durability of ibalizumab in combination with other antiretroviral therapies by comparing the clinical outcomes of patients receiving ibalizumab versus those patients not receiving ibalizumab.
Results from the study showed that treatment with ibalizumab reduced HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug resistant HIV.
These data were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, Calif.
"The data presented today suggest that ibalizumab can be a critical component of therapeutic regimens in the modern antiretroviral era. We look forward to validating these interim findings as we continue to enroll and monitor patients in this ongoing study," said Christian Marsolais, Senior Vice President and Chief Medical Officer of Theratechnologies.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.